老年非酒精性脂肪性肝病合并冠心病患者临床特点及危险因素分析*

doi:10.3969/j.issn.1672-5069.2021.05.025

Abstract

Abstract: Objective The aim of this study was to investigate the clinical feature and risk factors of elderly patients with nonalcoholic fatty liver diseases (NAFLD) and concomitant coronary heart disease (CHD). Methods The clinical data of 186 elderly patients with NAFLD admitted to our hospital between May 2018 and June 2020 were retrospectively analyzed, and all patients underwent coronary angiography. The univariate and multivariate Logistic regression analysis was applied to reveal the influencing factors of CHD in elderly NAFLD patients. Results Among 186 elderly patients with NAFLD, 75 (40.3%) patients had concomitant CHD; the percentage of diabetes mellitus, hypertension, smoking and fasting blood glucose (FPG), total blood cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, and insulin resistance index (HOMA-IR) in patients with CHD were significantly different as compared to those in patients without CHD (all P <0.05); the multivariate Logistic regression analysis showed that the increased BMI, concomitant diabetes mellitus, high blood FPG, TC, TG, and LDL-C levels were the independent risk factors for CHD in elderly NAFLD patients (all P < 0.05). Conclusion The incidence of CHD in elderly patients with NAFLD is high, and the related risk factors should be early under surveillance and appropriately controlled to improve thequality of life in elderly patients with NAFLD.

Key words: Nonalcoholic fatty liver diseases, Coronary heart disease, Clinical features, Risk factors, Elderly

Ma Shangji, Zheng Yang, Chen Xufeng, et al. Clinical feature and risk factors of elderly patients with nonalcoholic fatty liver diseases and concomitant coronary heart disease[J]. Journal of Practical Hepatology, 2021, 24(5): 705-708.

References

[1]Manne V, Handa P, Kowdley KV. Pathophysiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Clin Liver Dis, 2018, 22(1):23-37.
[2]Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology, 2020, 158(7):1851-1864.
[3]De Hert M, Detraux J, Vancampfort D. The intriguing relationship between coronary heart disease and mental disorders. Dialog Clin Neurosci, 2018, 20(1):31-40.
[4]Brouwers MCGJ, Simons N, Stehouwer CDA, et al. Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. Diabetologia, 2020, 63(2):253-260.
[5]Vita T, Murphy DJ, Osborne MT, et al. Association between nonalcoholic fatty liver disease at CT and coronary microvascular dysfunction at myocardial perfusion PET/CT. Radiology, 2019, 291(2):330-337.
[6]刘艳民, 曾静, 范建高. 2017亚太地区非酒精性脂肪性肝病指南简介. 实用肝脏病杂志, 2017, 20(5):7-9.
[7]Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery. Eur Heart J, 2018, 39(9):763-816.
[8]Brunner KT, Henneberg CJ, Wilechansky RM, et al. Nonalcoholic fatty liver disease and obesity treatment. Curr Obes Rep, 2019, 8(3):220-228.
[9]Lee SB, Park GM, Lee JY, et al. Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: an observational cohort study. J Hepatol, 2018, 68(5):1018-1024.
[10] Song DS, Chang UI, Kang SG, et al. Noninvasive serum fibrosis markers are associated with coronary artery calcification in patients with nonalcoholic fatty liver disease. Gut Liver, 2019, 13(6):658-668.
[11] Jaafar RF, Hajj Ali AM, Zaghal AM, et al. Fibroscan and low-density lipoprotein as determinants of severe liver fibrosis in diabetic patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol, 2019, 31(12):1540-1544.
[12] 严晨丽, 王晶晶, 王军. 非酒精性脂肪性肝病合并冠心病患者冠脉病变程度及其危险因素分析. 实用肝脏病杂志, 2018, 21(5):737-740.
[13] Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol, 2018, 14(2):99-114.
[14] Pemmasani G, Yandrapalli S, Aronow W. Sex differences in cardiovascular diseases and associated risk factors in non-alcoholic steatohepatitis. Am J Cardiovasc Dis, 2020, 10(4):362-366.
[15] 傅求真, 白玉蓉, 寇丹, 等. 脂肪肝患者ALT、AST、γ-GT水平及意义. 中华保健医学杂志, 2019, 21(5):454-455.
[16] Brouwers MCGJ, Simons N, Stehouwer CDA, et al. Relationship between nonalcoholic fatty liver disease susceptibility genes and coronary artery disease. Hepatol Commun, 2019, 3(4):587-596.
[17] Katsiki N, Tousoulis D. Diabetes mellitus and comorbidities: a bad romance. Hellenic J Cardiol, 2020, 61(1):23-25.
[18] Kothari S, Dhami-Shah H, Shah SR. Antidiabetic drugs and statins in nonalcoholic fatty liver disease. J Clin Exp Hepatol, 2019, 9(6):723-730.
[19] Mangla N,Ajmera VH, Caussy C, et al. Liver stiffness severity is associated with increased cardiovascular risk in patients with type 2 diabetes. Clin Gastroenterol Hepatol, 2020, 18(3):744-746.
[20] VanWagner LB, Ning H, Allen NB, et al. Twenty-five-year trajectories of insulin resistance and pancreatic β-cell response and diabetes risk in nonalcoholic fatty liver disease. Liver Int, 2018, 38(11):2069-2081.
[21] Samuel VT, Shulman GI. Nonalcoholic fatty liver disease, insulin resistance, and ceramides. N Engl J Med, 2019, 381(19):1866-1869.
[22] Ebrahimi S, Gargari BP, Aliasghari F, et al. Ramadan fasting improves liver function and total cholesterol in patients with nonalcoholic fatty liver disease. Int J Vitam Nutr Res, 2020, 90(2):95-102.
[23] Rhee EJ. Nonalcoholic fatty liver disease and diabetes: an epidemiological perspective. Endocrinol Metab, 2019, 34(3):226-233.
[24] Goodarzi R, Sabzian K, Shishehbor F, et al. Does turmeric/curcumin supplementation improve serum alanine aminotransferase and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease, A systematic review and meta-analysis of randomized controlled trials. Phytother Res, 2019, 33(3):561-570.
[25] Petta S, Wai-Sun Wong V, Bugianesi E, et al. Impact of obesity and alanine aminotransferase levels on the diagnostic accuracy for advanced liver fibrosis of noninvasive tools in patients with nonalcoholic fatty liver disease. Am J Gastroenterol, 2019, 114(6):916-928.

Clinical feature and risk factors of elderly patients with nonalcoholic fatty liver diseases and concomitant coronary heart disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Han Chengmei, Han Yongfeng, Wang Chunhua. Risk factors for acute kidney injury in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 883-886.
[2]	Guan Haiyan, Yang Wenbin. Clinical features and prognosis of patients with drug-induced liver injury [J]. Journal of Practical Hepatology, 2021, 24(5): 713-716.
[3]	Li Bianli, Xu Lihong. Differential diagnosis of drug-induced liver injury, drug-induced autoimmune hepatitis and autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(4): 460-463.
[4]	Zhang Jia, Jin Mingyuan, Du Yanyun, et al. Serum cytokine changes in patients with nonalcoholic fatty liver diseases and helicobacter pylori infection after clearance therapy [J]. Journal of Practical Hepatology, 2021, 24(4): 500-503.
[5]	Jiang Qiuwei, Huang Li, Yao Chaoguang. Clinical features and risk factors of esophagogastric variceal bleeding in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(4): 532-535.
[6]	Liu Xiangji, Liu Zhenxian, Wang Xiaoyan. Incidence of gallstone disease in middle-aged and elderly patients with nonalcoholic fatty liver disease and its relation to metabolic risk factors [J]. Journal of Practical Hepatology, 2021, 24(3): 363-366.
[7]	Jin Ying, Zhou Weizhen, Feng Shibing, et al. Prevalence of nonalcoholic fatty liver diseases in patients with intracerebral hemorrhage [J]. Journal of Practical Hepatology, 2021, 24(3): 367-370.
[8]	Kong Xuejie, Li Jiang, Li Haotian, et al. Clinical feature and efficacy of different prognostic scoring models in patients with acute-on-chronic liver failure with different underlying liver diseases [J]. Journal of Practical Hepatology, 2021, 24(3): 387-390.
[9]	Su Yayong, Xu Chengrun, Guo Yongmu, et al. Risk factors of death in patients with hepatitis B virus-related acute on chronic liver failure [J]. Journal of Practical Hepatology, 2021, 24(3): 391-394.
[10]	Gao Huiru, Gao Huibin, Peng Zhao, et al. Clinical feature and impacting factors of esophageal and gastric variceal bleeding in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(3): 395-398.
[11]	Chen Guangyu, Wang Hong, Wang Yaoshen, et al. Blood hemoglobin levels for risk of individuals apt to have nonalcoholic fatty liver disease risk [J]. Journal of Practical Hepatology, 2021, 24(1): 39-42.
[12]	Zhao Xiaochun,Zhong Qing,Liu Shuhong,et al. Changes and clinical implication of serum uric acid levels in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2021, 24(1): 55-58.
[13]	Li Zhao, Huang Zansong , Li Fan. Application of fenofibrate and bicyclol combination in treatment of patients with non-alcoholic fatty liver diseases and changes of hepatic PPARγ₂ [J]. Journal of Practical Hepatology, 2021, 24(1): 59-62.
[14]	Chen Jinyu, Guo Xiaoxia, Zhong Xiaoni. Efficacy of bifidobacterium triple viable capsuleand metformin in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 63-66.
[15]	Sun Wenxia, Wu Shuzhi. Clinical features of IgG4-related sclerosing cholangitis:systemic literature review of 100 cases [J]. Journal of Practical Hepatology, 2021, 24(1): 83-86.